Immunicum – executive interview

Published on 7 June 2022

Immunicum is a clinical-stage immunoncology company based in Sweden and the Netherlands. The company specialises in allogeneic dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumours. Its lead clinical asset in development (Phase II, acute myeloid leukaemia) is based on intratumoural priming and cancer relapse vaccination.

In this video, the company’s chief executive officer, Erik Manting, provides an overview of the company’s strategy and differentiated approach.

Share this with friends and colleagues